AlAu!ustj905mj"}  Eighth  Decennial  Revision  of  Pharmacopoeia.  357 
as  Dr.  Rice  pointed  out  in  the  paper  quoted  above,  a  peculiarly  dif- 
ficult problem.  This  problem  is  made  still  more  intricate  by  the 
varying  laws  and  regulations  that  exist  in  the  different  countries 
relating  to  proprietary  rights  in  patents  and  trade-marks. 
To  illustrate  some  of  the  complications  and  differences  that  future 
revision  committees  will  have  to  contend  with  it  may  be  well  to 
compare  the  trade  and  the  accepted  chemical  name  of  several  of 
these  newly-admitted  synthetic  preparations  with  the  official  titles 
that  are  given  them  in  the  new  U.S. P.,  the  B.P.  and  last  edition  of 
the  German  Pharmacopoeia. 
Antipyrine.  Phenyldimethylpyrazolon. 
U.S. P.  Antipyrina. 
B.P.  Phenazonum. 
Ger.  Phar.    Pyrazolonum  phenyldimethylicum. 
Chloralamid.  Chloralformamide. 
U.S.P.  Chloralformamidum. 
Ger.  Phar.    Chloralum  formamidatum. 
Phenacetine.    Par  acetphenetidin. 
US.P.  Acetphenetidinum. 
B.P.  Phenacetinum. 
Ger.  Phar.  Phenacetinum. 
Sulphonal.  Diethylsulphonedimethylmethane. 
U.S.P.  Sulphonmethanum. 
B.P.  Sulphonal. 
Ger.  Phar.  Sulfonalum. 
Trional.  Diethylsulphonemethylethylmethane. 
U.S.P.  Sulphonethylmethanum. 
Ger.  Phar.  Methylsulfonalum. 
Doses. — The  instructions  embodied  in  the  "  General  Principles  to  be 
Followed  in  Revising  the  Pharmacopoeia,"  under  the  sub-heading 
"  Doses,"  direct  that  the  Committee  on  Revision  "  state  the  average 
approximate  (but  neither  a  minimum  nor  a  maximum)  dose  for 
adults,  and,  when  deemed  advisable,  also  for  children.  The  metric 
system  to  be  used,  and  the  approximate  equivalents  in  ordinary 
weights  and  measures  inserted  in  parenthesis."  In  executing  these 
indisputably  plain  and  explicit  instructions,  the  members  of  the 
Committee  on  Revision  cannot  be  said  to  have  followed  them  too 
